Compare NTR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTR | BIIB |
|---|---|---|
| Founded | 2017 | 1978 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | NTR | BIIB |
|---|---|---|
| Price | $59.28 | $180.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 23 |
| Target Price | $63.76 | ★ $176.48 |
| AVG Volume (30 Days) | ★ 2.5M | 2.0M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.68% | N/A |
| EPS Growth | ★ 150.34 | N/A |
| EPS | 3.70 | ★ 10.97 |
| Revenue | ★ $25,671,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $6.21 | $2.97 |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | ★ $16.02 | $16.42 |
| Revenue Growth | 0.45 | ★ 4.77 |
| 52 Week Low | $43.70 | $110.04 |
| 52 Week High | $65.08 | $185.17 |
| Indicator | NTR | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 72.54 |
| Support Level | $54.52 | $165.75 |
| Resistance Level | $60.35 | $183.93 |
| Average True Range (ATR) | 1.42 | 5.70 |
| MACD | 0.31 | 0.91 |
| Stochastic Oscillator | 75.48 | 81.64 |
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).